Is Pulse Health Limited a screaming buy?

Private hospital operator Pulse Health Limited (ASX: PHG) could be a bargain buy after the share price halved since May 18. That includes another 12.5% fall to 21 cents today.

The company’s share price plunged 30% in one day to 30 cents a share in May, after Pulse announced that underlying earnings before interest, tax, depreciation and amortisation (EBITDA) would be between $8 million and $9.2 million for the 2016 financial year (FY16) (excluding recent acquisitions).

Pulse blamed the fall on a recent slowdown in activity at its three rehabilitation hospitals.

Looks cheap

Howewer, on the plus side, with a market cap of just $53 million and net cash of $2.7 million, even at the lower end of guidance, Pulse Health is trading on an EV/EBITDA ratio of just over 6x.

By comparison, Ramsay Health Care Limited (ASX: RHC) and Healthscope Ltd (ASX: HSO) trade on multiples of 15x – which suggests that Pulse is cheap.

Acquisitions to add value

In December 2015, Pulse announced the acquisition of a specialist surgical hospital in New Zealand, and five day surgeries and one acute hospital in Australia in early December for an upfront payment of $48 million and further earn outs. At the time, Pulse was also guiding to FY17 EBITDA of $18.1 million, including a $6.4 million contribution from the acquisitions.

However, Pulse has announced this week that it is not proceeding with the Waikiki Private Hospital and Westminster Day Surgery acquisitions. Those assets were expected to contribute $1.6 million of the incremental $6.4 million of FY17 EBITDA.

In simple terms that means the acquisitions announced in December 2015 should contribute $4.8 million in additional EBITDA in FY17, bringing FY17 EBITDA guidance down to $16.5 million. Those acquisitions will also deliver revenues and earnings this financial year – although it won’t be a full 12 months.

Takeover target?

Given the acquisition of Vision Eye Institute and its day surgeries last year by Chinese company Jangho, its attractive and diverse assets, Pulse could be a takeover target as well – particularly at current prices.

Foolish takeaway

While the recent earnings downgrade looks bad, the 50% fall in the share price appears unjustified, and Pulse could be a bargain at these prices. Even if earnings are hit in the short term, Pulse does have some strong tailwinds behind it in an ageing population.

Could these 5 dividend shares be better bets?

Discover The Motley Fool's top 5 ASX dividend stock ideas for 2016 to get you started building a more diversified income portfolio that is paying you back!

The report is free! No credit card required.

Motley Fool writer/analyst Mike King doesn't own shares in any companies mentioned. You can follow Mike on Twitter @TMFKinga

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.